Vosoritide (trade name VOXZOGO) is a drug used to treat chondroplasia with open epiphyses in children. This article will detail the dosage, precautions for use, and dietary recommendations for patients during use of Vosoritide.

Dosage and Administration of Vosoritide

Accurately adjusting the dose of Vosoritide according to the patient's weight and strictly following the doctor's instructions for daily injections are important steps in confirming the effectiveness of treatment.

Recommended Dosage and Administration

The recommended dose of Vosoritide is based on the patient's weight and requires subcutaneous injection once a day. Generally, patients should inject at the same time every day. Vosoritide must be reconstituted before use, and its concentration can be 0.8mg/mL or 2mg/mL, depending on the doctor's advice. In the case of a missed dose, if it is found within 12 hours after the scheduled time, the missed dose can be made up; if it exceeds 12 hours, the dose should be skipped and the next dose should be continued according to the regular schedule.

Growth monitoring and dose adjustment

In order to evaluate the efficacy and adjust the treatment plan in time, the patient's weight, growth and physical development status need to be monitored every 3 to 6 months. Once it is confirmed that there is no further growth potential, that is, after the epiphysis is closed, Vosoritide can be permanently discontinued.

Regular monitoring not only helps to optimize the treatment effect, but also makes it clear that each patient gets the most appropriate dose adjustment.

Precautions for the use of Vosoritide

Managing the risk of hypotension through appropriate precautions can improve the safety and tolerability of treatment.

Prevention of the risk of hypotension

Vosoritide may cause a transient drop in blood pressure, so patients should eat enough food and drink about 240 to 300 ml of fluid within one hour before injection. This helps reduce the risk of related symptoms such as dizziness, fatigue and nausea caused by hypotension.

Use in special populations

Vosoritide should be used with caution for pregnant women, breastfeeding women and patients with renal dysfunction. There is currently no safety data on the use of Vosoritide in pregnant women, and breastfeeding women should also consider the possible effects of breastfeeding on their children. In patients with renal impairment, eGFR≥60ml/min/1.73m2 does not require dose adjustment, but it is not recommended for patients with eGFR<60mL/min/1.73m2.

Personalized treatment planning based on the specific conditions of different populations can better maintain patient safety.

Dietary precautions for patients with Vosoritide

Reasonable dietary arrangements are important for improving the efficacy of Vosoritide and reducing discomfort during treatment.

Preparation before injection

To reduce the occurrence of hypotension and its related symptoms, patients should eat enough food and drink about 240 to 300 ml of fluid within an hour before each injection of Vosoritide. This not only helps maintain blood pressure stability, but also reduces potential adverse reactions.

Daily diet structure

During treatment with Vosoritide, maintaining a balanced diet is very important to promote bone health and overall growth. Foods rich in protein, vitamin D and calcium help support bone growth. Avoid high-sugar and high-fat foods to prevent unnecessary weight gain and other health problems.

Understanding the dosage and usage of Vosoritide, mastering the precautions for medication, and paying attention to the patient's dietary recommendations during treatment are important for achieving the best treatment effect. Correct medication guidance and lifestyle adjustments can not only enhance the efficacy of the drug, but also significantly improve the patient's quality of life.